Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Streetwise Reports, Streetwise Reports
0 Comments| August 7, 2019

{{labelSign}}  Favorites

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases.

Click to enlarge

Clinical stage biotech company Allakos Inc. (ALLK:NASDAQ) announced second quarter earnings today for the period ending June 30, 2019, and released a statement that it had successfully completed its phase 2 study for AK002 used in the treatment of eosinophil and mast cell related diseases. The market has responded very favorably to the news with the firm's shares opening nearly 100% higher today.

In the earnings report, Allakos, still a clinical stage company, did not report any revenue in the quarter. The firm stated that research and development (R&D) expenses were $14.1 million in Q2/19 compared to $7.1 million in Q2/18. The increase in R&D expenses was primarily related to an increase in contract research and development activities in support of the advancement of AK002, the company's lead antibody, as well as an increase in consulting and personnel-related costs.

General and administrative expenses (SG&A) were $5.9 million in Q2/19 versus $2.4 million in Q2/18. The firm noted that the increase in SG&A expenses was primarily attributable to an increase in personnel-related costs as a result of an increase in employee headcount, and incremental expenses incurred from outside professional service expenses associated with becoming a publicly traded company in July 2018.

The company reported a net loss of $19.1 million Q2/19 compared to $9.4 million Q2/18, an increase of $9.7 million. Net loss per basic and diluted share improved to $0.44 for Q2/19 compared to $4.17 in Q2/18. The firm ended Q2/19 with $153.1 million in cash, cash equivalents and marketable securities.

In a separate release today, the company announced positive results from its phase 2 randomized, double-blind, placebo-controlled trial of AK002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis. The firm reported "all AK002 dose arms showed clinically meaningful and statistically significant benefits compared to placebo on all prespecified primary and secondary endpoints, including gastrointestinal tissue eosinophil counts and patient reported disease symptoms...Statistically significant differences in patient symptoms between the active and placebo groups occurred one day following AK002 administration...patients with comorbid eosinophilic esophagitis treated with AK002 experienced statistically significant decreases in esophageal eosinophil counts and substantial reductions in patient reported dysphagia symptoms."

Dr. Evan Dellon, M.D., a principal investigator of the study and professor of gastroenterology at the University of North Carolina, Chapel Hill, stated, "Eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic esophagitis are severe debilitating diseases with no approved therapies...AK002 is unique in that it targets both eosinophils and mast cells, two major effector cell types that cause disease-related tissue damage. In this study, AK002 reduced eosinophil and mast cell counts and showed a statistically significant improvement in disease symptoms one day after administration." Dr. Dellon elaborated further, "These are clinically meaningful changes, and these data suggest that AK002 could provide rapid and sustained benefit in patients with eosinophil gastrointestinal diseases and I look forward to the continued development of AK002 in these severe orphan conditions."

Eosinophilic gastritis, eosinophilic gastroenteritis and eosinophilic esophagitis are severe orphan inflammatory diseases characterized by the presence of high levels of eosinophils in the stomach, duodenum or esophagitis, respectively. Allakos has received orphan drug designation for AK002 in eosinophilic gastritis and eosinophilic gastroenteritis.

Allakos describes itself as a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory and proliferative diseases. The firm's lead antibody AK002, which has been tested in five clinical studies, targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. AK002 has been shown to inhibit mast cells and deplete eosinophils, and in the studies, AK002 eliminated blood eosinophils and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, eosinophilic esophagitis, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.

Allakos shares opened today up nearly 100% higher at $61.00 (+$30.00, + 96.77%) compared to Friday's closing price of $31.00. Since the open, shares have traded between $60.34 and $71.95, setting both 52-week and all-time intraday highs on more than 15 times average volume. At present, shares are trading at $71.07 (+40.07, +129.26%).

Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.
Click to enlarge Newsletter Sign-Up

1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer . This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.


{{labelSign}}  Favorites


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media


Featured Company